SJP 0118

Drug Profile

SJP 0118

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Developer Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Blepharitis; Infectious conjunctivitis; Ocular inflammation

Most Recent Events

  • 28 Jul 2016 Senju Pharmaceutical completes a phase I trial in Healthy volunteers (In the elderly) in Japan before July 2016 (Instillation) (UMIN000019877)
  • 28 Jul 2016 Senju Pharmaceuticals completes a phase-III trial in Blepharitis and Ocular inflammation in Japan before July 2016 (Instillation) (UMIN000019698)
  • 28 Jul 2016 Senju Pharmaceutical completes a phase III trial for Infectious conjunctivitis in Japan before July 2016(UMIN000018481)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top